BIOGEN INC

Biogen’s litifilimab shows breakthrough Phase‑2 success in cutaneous lupus erythematosus, promising new high‑margin treatment and a strategic shift away from Alzheimer’s research.

Biogen’s latest update reveals promising Phase 1b results for salanersen in spinal muscular atrophy, outlining a Phase 3 plan to evaluate safety, efficacy, and combination therapy while navigating accelerated regulatory pathways.

Biogen’s latest data on higher‑dose nusinersen, salanersen, and zorevunersen show promise for spinal muscular atrophy and Dravet syndrome, highlighting progress in precision antisense therapies for rare neurological diseases.

Biogen’s Q4 2025 earnings reveal cost‑cutting tactics amid patent cliffs, a shift toward Alzheimer’s and rare‑disease drugs, and a focus on patient‑centric market access strategies.

Biogen’s Q4 2025 earnings show a 5% sales dip from its MS line but strong cost cuts and new Alzheimer’s/rare‑disease revenue, positioning 2026 earnings above forecasts.

Biogen’s Q4 2023 results beat estimates, driven by Leqembi’s 42 % sales surge and a 30 % drop in Alzheimer’s decline, positioning a 2026 revenue lift to $1.75 billion.

Biogen’s LEQEMBI IQLIK subcutaneous autoinjector gains FDA priority review—boosting early Alzheimer’s access, patient adherence, and investor confidence.

Biogen’s Q4 earnings hit, high‑dose SPINRAZA approval, and patent‑cliff strategy reveal how the biotech giant balances R&D costs, market access and M&A to protect revenue and stay ahead of rivals in neurology.

Biogen gains analyst backing and China’s approval of LEQEMBI’s home‑administered autoinjector, boosting access to early Alzheimer’s treatment and showing stronger growth prospects.

Biogen’s latest update reveals EMA approval for high‑dose nusinersen and new natural‑history data on Dravet syndrome, highlighting breakthrough gene‑editing and ASO pipelines that could transform rare neurological care.